Drugs / Aspirine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00152646 | Mar 2005 → Jan 2008 | peripheral arterial disease | University Hospital, Angers | Unknown | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02594410 Background | Sep 2011 → Mar 2014 | hypertensive disorder | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2009-06-02 | Astellas Pharma Inc | Results NEWLY PRESENTED DATA ON GASTER® SHOW PREVENTION OF PEPTIC ULCERS IN USERS OF LOW-DOSE ASPIRINE astellas.com ↗
After 12 weeks of treatment, incidence of all lesions diagnosed with endoscope in patients taking Gaster showed significant difference (p<0.00001) in this trial (5.9% in patients taking Gaster 20-mg twice daily and 33.0% in patients taking placebo). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2009-06-02 | Astellas Pharma Inc | NEWLY PRESENTED DATA ON GASTER® SHOW PREVENTION OF PEPTIC ULCERS IN USERS OF LOW-DOSE ASPIRINE astellas.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aspirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00152646 ↗ |